Fig. 4: Artesunate-mediated anti-obesity effect is GDF15 dependent.
From: Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis
Diet-induced obese mice injected with adeno-associated virus expressing shControl or shGDF15 were treated daily with either vehicle or artesunate (ART; 20 mg/kg) for 21 days. A Cumulative food intake and B changes in body weight in obese shGDF15 mice with ART or vehicle over the treatment period (n = 6 for all treatment groups) C, D Plasma glucose level and area under the curve (AUC) during the intraperitoneal glucose tolerance tests (n = 6 for all treatment groups) E, F Plasma glucose level and AUC during the insulin tolerance tests (n = 6 for all treatment groups). Data are reported as mean ± s.e.m.; two-way ANOVA followed by Tukey’s multiple comparison post-hoc test (A–C) and Fisher’s LSD post-hoc test (E), one-way ANOVA followed by Fisher’s LSD post-hoc test (D, F). For the curve plots, the p-value represents the comparison between shControl + ART and shGDF15 + ART treatment groups (C, E). Source data are provided as a Source Data file.
